Global expansion Curia is actively expanding manufacturing and development capacity across multiple regions, including Glasgow in the UK and Albuquerque in the US, signaling opportunity to engage on scale-up programs, regulatory support for new facilities, and capacity-driven partnerships.

Diversified capabilities With capabilities spanning small molecules, generic APIs and biologics, plus regulatory, analytical, drug substance and sterile fill-finish services, Curia presents cross-sell potential across discovery to commercialization for varied client pipelines.

Strategic acquisitions The company has grown via acquisitions (Crystal Pharma, Euticals, Gadea, LakePharma, Ragactives, Integrity Bio), indicating a readiness to integrate new capabilities and attract clients seeking broadened CDMO offerings and seamless transitions.

Massachusetts footprint Historically strong in Massachusetts with recognition as Manufacturer of the Year, yet recent facility closures and headcount reductions suggest a focus on optimization; opportunities may exist to engage on strategic refits, legacy asset utilization, and migration of programs to expanding sites.

Operational modernization Investments in aseptic API suites (Valladolid, Spain) and a push toward upgraded drug product capacity point to modernization momentum; target customers with sterile fill-finish, high-value aseptics, and regional supply chain resilience needs.